These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25966862)

  • 1. Use of the levonorgestrel intrauterine system in postmenopause.
    Al-Azzawi F
    Climacteric; 2015 Jun; 18(3):431-2. PubMed ID: 25966862
    [No Abstract]   [Full Text] [Related]  

  • 2. Levonorgestrel and breast cancer risk - clarified.
    Al-Azzawi F
    Climacteric; 2015 Jun; 18(3):434. PubMed ID: 25966864
    [No Abstract]   [Full Text] [Related]  

  • 3. Contraception during the perimenopause.
    Baldwin MK; Jensen JT
    Maturitas; 2013 Nov; 76(3):235-42. PubMed ID: 23932427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The contraceptive needs of the perimenopausal woman.
    Erkkola R
    Climacteric; 2014 Dec; 17(6):723-4. PubMed ID: 25562077
    [No Abstract]   [Full Text] [Related]  

  • 5. Author's reply: To PMID 24990143.
    Erkkola R
    Climacteric; 2015 Jun; 18(3):432-3. PubMed ID: 25966863
    [No Abstract]   [Full Text] [Related]  

  • 6. Contraception and hormonal management in the perimenopause.
    Long ME; Faubion SS; MacLaughlin KL; Pruthi S; Casey PM
    J Womens Health (Larchmt); 2015 Jan; 24(1):3-10. PubMed ID: 24773233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-contraceptive benefits of hormonal contraceptive use during perimenopause?
    Mendoza N; Sánchez-Borrego R
    Maturitas; 2014 May; 78(1):72. PubMed ID: 24630129
    [No Abstract]   [Full Text] [Related]  

  • 8. Health benefits of hormonal contraception.
    Baldwin MK; Jensen JT
    Maturitas; 2014 May; 78(1):73. PubMed ID: 24685288
    [No Abstract]   [Full Text] [Related]  

  • 9. The contraception needs of the perimenopausal woman.
    Hardman SM; Gebbie AE
    Best Pract Res Clin Obstet Gynaecol; 2014 Aug; 28(6):903-15. PubMed ID: 24990143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contraception in the perimenopause--old and new.
    Gebbie AE; Hardman SM
    Menopause Int; 2010 Mar; 16(1):33-7. PubMed ID: 20424284
    [No Abstract]   [Full Text] [Related]  

  • 11. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.
    Eisenberg DL; Schreiber CA; Turok DK; Teal SB; Westhoff CL; Creinin MD;
    Contraception; 2015 Jul; 92(1):10-6. PubMed ID: 25934164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices.
    Cohen R; Sheeder J; Arango N; Teal SB; Tocce K
    Contraception; 2016 Feb; 93(2):178-83. PubMed ID: 26475368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaginal flora changes on Pap smears after insertion of levonorgestrel-releasing intrauterine device.
    Donders GG; Berger J; Heuninckx H; Bellen G; Cornelis A
    Contraception; 2011 Apr; 83(4):352-6. PubMed ID: 21397094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why perimenopausal women should consider to use a levonorgestrel intrauterine system.
    Wildemeersch D
    Gynecol Endocrinol; 2016 Aug; 32(8):659-661. PubMed ID: 26930021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review.
    Depypere H; Inki P
    Climacteric; 2015; 18(4):470-82. PubMed ID: 25553775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond.
    Rose SB; Garrett SM; Stanley J
    Contraception; 2015 Jul; 92(1):17-25. PubMed ID: 25818594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovations in contraception: a review.
    Zurawin RK; Ayensu-Coker L
    Clin Obstet Gynecol; 2007 Jun; 50(2):425-39. PubMed ID: 17513928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new LNG-releasing IUS: a new opportunity to reduce the burden of unintended pregnancy.
    Cristobal I; Neyro JL; Lete I
    Eur J Obstet Gynecol Reprod Biol; 2015 Jul; 190():58-64. PubMed ID: 25988513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting reversible contraception: a review in special populations.
    Prescott GM; Matthews CM
    Pharmacotherapy; 2014 Jan; 34(1):46-59. PubMed ID: 24130075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.